Thursday, November 21, 2013
This week in therapeutics
Publication and contact
Neurotrophic tyrosine kinase receptor 1 (NTRK1;
In vitro and mouse studies suggest TrkA inhibitors could
help treat a subgroup of patients with lung cancer. In tumor samples from 91
patients with lung cancer, 3 patients carried NTRK1 gene fusions. In
noncancerous cells, expression of the gene fusions caused constitutive
activation of TrkA, the protein encoded by NTRK1, and induced
proliferation, anchorage-independent growth and tumor development when
implanted in mice. In fusion-expressing cells, TrkA inhibitors including ARRY-470
blocked TrkA autophosphorylation and cell proliferation. Next steps include a
clinical trial using Trk inhibitors in biomarker-selected patients.
BioPharma Inc. has ARRY-470 in preclinical testing for
Medical Sciences s.r.l. has PHA-848125,
an inhibitor of cyclin
dependent kinases (CDKs)
and TrkA, in Phase II testing to treat cancer.
Inc. and Tesaro
Inc. have the dual TrkA and anaplastic
lymphoma kinase (ALK)
in Phase I/II testing to treat non-small cell lung cancer (NSCLC).
Published online Nov. 21, 2013
Patent application filed;
licensing status undisclosed
Vaishnavi, A. et al.
Nat. Med.; published online Oct. 27, 2013;
Contact: Robert C. Doebele, University of Colorado Denver
School of Medicine, Aurora, Co.
Contact: Pasi A. Jänne, Dana-Farber Cancer Institute, Boston,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]